Professor, Consultant Interventional Cardiology
Lund University
Lund, Sweden
Dr David Erlinge is Professor of Cardiology at Lund University, Sweden Prof Erlinge is an interventional cardiologist focusing on PCI with a clinical interest in acute coronary syndromes. He is chairman of the Swedish PCI register (SCAAR) member of the board of SWEDEHEART.
He has been involved in the developing and leading registry based randomized clinical trials (RRCT) from TASTE, IFR-SWEDEHEART, DETO2X and was the leader of the pharmaceutical RRCT VALIDATE-SWEDEHEART, DAPA-MI and the diagnostic vulnerable plaque trial PROSPECT II.
Disclosure(s): chiesi, bracco: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); kaminari, medical: Consulting Fees (e.g., advisory boards) (Ongoing)
The Role of Lp(a) and Lipidomics in Plaque Development From PROSPECT II
Sunday, March 8, 2026
4:29 PM - 4:37 PM EST
Panel Discussion | Atherosclerosis Therapeutic Options and Management - What is Promising?
Sunday, March 8, 2026
5:15 PM - 5:35 PM EST
Comparison Between "Leave Nothing Behind" Technologies | DCB and Bioadaptor
Monday, March 9, 2026
11:35 AM - 11:43 AM EST
Panel Discussion | BRS Biodegradable Polymers Bioadaptors | Is There a Future for the Technology?
Monday, March 9, 2026
11:59 AM - 12:30 PM EST
Registry-Based Randomized Trials
Monday, March 9, 2026
9:09 AM - 9:17 AM EST
Panel Discussion | From EFS to Real World Data
Tuesday, March 10, 2026
11:44 AM - 12:10 PM EST